Friday 6 November 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue: +13.3%
EPS: −9.42%
Free cash flow: +364.6%
Total debt: −4.00%

Quarter to September 2026, against a year earlier

Dividend growth 5 yrs

67.28 0.29 −0.43%

Follow RPRX

Alert me

Market cap: $39.0B
P/E: 37.6×
Fwd P/E: 27.3×
Dividend yield: 1.37%
F-score: 5/9
Altman Z: 1.61
Beneish M: −2.83
Dividend safety: 41/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

	Older periods	Dec '25	Mar '26	Jun '26	Sep '26
P/E ratio Full definition →	+8 more quarters Free account	21.71	25.25	30.31	32.64
P/S ratio Full definition →		6.98	8.59	9.84	9.95
P/FCF ratio Full definition →		4.72	17.53	19.05	25.63
P/Operating CF Full definition →		20.08	29.17	34.26	37.94
P/B ratio Full definition →		1.71	2.11	2.55	2.66
Price to Tangible BV Full definition →		1.89	2.32	2.82	2.93
EV/Sales Full definition →		10.48	12.01	13.04	13.02
EV/EBITDA Full definition →		15.65	18.04	21.38	22.25
EV/Operating CF Full definition →		10.01	11.22	11.11	11.51
EV/FCF Full definition →		7.09	24.51	25.25	33.55
Quick Ratio Full definition →		1.05	1.19	1.38	0.49
Current Ratio Full definition →		2.40	2.66	2.80	1.29
Net Debt/EBITDA Full definition →		20.93	14.60	57.16	19.13
Debt/Assets Full definition →		45.62%	45.20%	45.22%	44.13%
Debt/Equity Full definition →		0.92	0.90	0.92	0.88
Asset Turnover Full definition →		0.13	0.13	0.13	0.13
Operating CF/Net income Full definition →		3.84	2.44	40.73	4.74
Capex/Depreciation Full definition →		0.00	(51.17)	(27.81)	(29.40)
Interest Coverage Full definition →		4.12	6.01	1.42	4.54
Research and Development Expense of Revenue Full definition →		8.12%	6.31%	14.51%	9.15%
Selling, General and Administrative Expense of Revenue Full definition →		26.41%	25.29%	24.01%	21.75%
Intangible Assets out of Total Assets Full definition →		0.05	0.05	0.05	0.05
Share Based Compensation of Revenue Full definition →		20.22%	19.35%	15.88%	15.20%
Graham Net Nets Full definition →		(0.50)	(0.40)	(0.33)	(0.31)
Graham Number Full definition →		30.09	31.19	30.25	29.72
Earnings Yield Full definition →		4.61%	3.96%	3.30%	3.06%
Free Cash Flow Yield Full definition →		21.18%	5.71%	5.25%	3.90%
Revenue per Share Full definition →		1.45	1.44	1.51	1.55
Operating CF per Share Full definition →		1.92	1.64	1.64	1.54
Capex per Share Full definition →		0.00	(1.04)	(0.56)	(0.63)
Free Cash Flow per Share Full definition →		1.92	0.61	1.07	0.91
Cash per Share Full definition →		1.48	1.39	1.88	1.22
Shareholders Equity per Share Full definition →		22.60	22.75	21.99	21.96
Interest Debt per Share Full definition →		0.00	0.00	0.00	0.00
Book value per Share Full definition →		22.60	22.75	21.99	21.96
Free Cash Flow Full definition →		827.15	265.87	477.44	407.08
Working Capital Full definition →		891.88	890.13	1,133.64	346.56
Capital Expenditures Full definition →		—	(452.37)	(251.02)	(279.00)
Net Current Asset Value Full definition →		(8,377.75)	(8,452.77)	(8,269.49)	(8,140.38)
EV/EBIT Full definition →		15.98	18.45	21.88	22.79
Capex to Sales Full definition →		0.00	0.72	0.37	0.40
Price to Operating Income Full definition →		10.65	13.19	16.51	17.41
Other line items
Average Receivables Full definition →		28.14	25.65	29.61	32.42
Average Payables Full definition →		16.39	31.56	27.89	36.42
Average Assets Full definition →		18,921.75	18,711.84	19,071.39	19,404.25
Average Common Equity Full definition →		10,028.65	9,862.75	9,644.33	9,708.07

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026

Stockrow Weekly